CDSCO Panel Accepts BE Report, Tells Intas Pharma to Conduct Phase III Trial for Semaglutide
New Delhi: In response to a proposal submitted by Intas Pharmaceuticals, the Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has recommended acceptance of the bioequivalence (BE) study report and granted permission to conduct a Phase III clinical trial for the antidiabetic drug Semaglutide as per the submitted protocol.
This came after the firm presented its proposal for the Phase III trial of Semaglutide injection in patients with Type 2 Diabetes Mellitus, along with the BE study report. The trial will be conducted according to protocol no. 0130-24, version 1.0, dated 03.02.2025.
Semaglutide is an incretin mimetic, classified as a glucagon-like peptide-1 (GLP-1) receptor agonist. It helps regulate blood sugar by enhancing glucose-dependent insulin secretion, suppressing glucagon, and delaying gastric emptying. These effects support both glycemic control and weight management.
At the recent SEC meeting for Endocrinology and Metabolism held on 14th May 2025, the expert panel reviewed the full submission.
“After detailed deliberation, the committee recommended accepting the BE study report and conducting the Phase III clinical trial as per the submitted protocol,” the SEC stated.
The proposed Semaglutide injection strengths include:
0.68 mg/mL (1 mg/1.5 mL), 1.34 mg/mL (2 mg/1.5 mL and 4 mg/3 mL), 2.27 mg/mL (6.8 mg/3 mL), and 3.2 mg/mL (9.6 mg/3 mL) in prefilled pens.
Also Read: Sanofi Gets CDSCO Panel Nod to Update Aldurazyme Prescribing Information
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.